Belatacept-versus cyclosporine-based immune suppression in renal transplant recipients with pre-existing diabetes

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 11, 2011, Pages 2696-2704

  Rostaing, Lionel ^a   Neumayer, Hans H ^b   Reyes Acevedo, Rafael ^c   Bresnahan, Barbara ^d   Florman, Sander ^e   Vitko, Stefan ^f   Heifets, Michael ^g   Xing, Jun ^g   Thomas, Dolca ^g   Vincent, Flavio ^h  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Centenario Hospital Miguel Hidalgo   (Mexico)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e MOUNT SINAI MEDICAL CENTER   (United States)

^f INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^g BRISTOL MYERS SQUIBB   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BELATACEPT; CYCLOSPORIN;

ADULT; ARTICLE; BLOOD TOXICITY; CARDIOVASCULAR RISK; CONNECTIVE TISSUE DISEASE; DIABETES MELLITUS; DRUG EFFECT; ENDOCRINE DISEASE; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART DISEASE; HEPATOBILIARY DISEASE; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFESTATION; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; LYMPHATIC SYSTEM DISEASE; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDIASTINUM DISEASE; METABOLIC DISORDER; MORTALITY; MUSCULOSKELETAL DISEASE; NUTRITIONAL DISORDER; OUTCOME ASSESSMENT; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; SKIN DISEASE; STATISTICAL SIGNIFICANCE; SURVIVAL; URINARY TRACT DISEASE; VASCULAR DISEASE;

ADULT; AGED; ANALYSIS OF VARIANCE; CYCLOSPORINE; DIABETES COMPLICATIONS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 80655139682     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00270111     Document Type: Article

References (27)

1. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK: Long-term survival in renal transplant recipients with graft function. Kidney Int 57: 307-313, 2000.
2. Rigatto C, Parfrey P, Foley R, Negrijn C, Tribula C, Jeffery J: Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol 13: 1084-1090, 2002.
3. Kasiske BL, Chakkera HA, Roel J: Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 11: 1735-1743, 2000
4. Cosio FG, Hickson LJ, Griffin MD, Stegall MD, Kudva Y: Patient survival and cardiovascular risk after kidney transplanta tion: The challenge of diabetes. Am J Transplant 8: 593-599, 2008
5. Orsenigo E, Socci C, Carlucci M, Zuber V, Fiorina P, Gavazzi F, Secchi A, Di Carlo V, Staudacher C: Multivariate analysis of factors affecting patient and graft survival after renal transplant. Transplant Proc 37: 2461-2463, 2005
6. Revanur VK, Jardine AG, Kingsmore DB, Jaques BC, Hamilton DH, Jindal RM: Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant 15: 89-94, 2001
7. Gonzalez-Posada JM, Hernandez D, Bayes GB, Garcia PJ, Rivero SM: Impact of diabetes mellitus on kidney transplant recipients in Spain. Nephrol Dial Transplant 19[Suppl 3]: iii57-iii61, 2004
8. Kronson JW, Gillingham KJ, Sutherland DE, Matas AJ: Renal transplantation for type II diabetic patients compared with type I diabetic patients and patients over 50 years old: A single-center experience. Clin Transplant 14: 226-234, 2000.
9. Miller LW: Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2: 807-818, 2002
10. Halloran PF: Immunosuppressive drugs for kidney transplantation. N Engl J Med 351: 2715-2729, 2004
11. Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, Uchida K, Pescovitz MD, Marchetti P, Tuncer M, Citterio F, Wiecek A, Chadban S, El Shahawy M, Budde K, Goto N: Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 7: 1506-1514, 2007
12. Roland M, Gatault P, Doute C, Buchler M, Al Najjar A, Barbet C, Chatelet V, Marliere JF, Nivet H, Lebranchu Y, Halimi JM: Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation. Transpl Int 21: 523-530, 2008
13. Joss N, Staatz CE, Thomson AH, Jardine AG: Predictors of new onset diabetes after renal transplantation. Clin Tran plant 21: 136-143, 2007
14. Hjelmesaeth J, Hartmann A, Kofstad J, Stenstrom J, Leivestad T, Egeland T, Fauchald P: Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 64: 979-983, 1997
15. Johnston O, Rose CL, Webster AC, Gill JS: Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 19: 1411-1418, 2008
16. Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, Massari P, Mondragon-Ramirez GA, Agarwal M, Di Russo G, Lin CS, Garg P, Larsen CP: A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 10: 535-546, 2010
17. Durrbach A, Pestana JM, Pearson T, Vincenti F, Garcia VD, Campistol J, Rial MC, Florman S, Block A, Di Russo G, Xing J, Garg P, Grinyo J: A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 10: 547-557, 2010
18. Grinyo J, Charpentier B, Pestana JM, Vanrenterghem Y, Vincenti F, Reyes-Acevedo R, Apanovitch AM, Gujrathi S, Agarwal M, Thomas D, Larsen CP: An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 90: 1521-1527, 2010
19. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 7: 177-188, 1986
20. David KM, Morris JA, Steffen BJ, Chi-Burris KS, Gotz VP, Gordon RD: Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre transplant diabetes. Clin Transplant 19: 279-285, 2005
21. Shen J, Block A, Townsend R, You X, Shen Y, Zhou S, Geng D, McGirr N, Soucek K, Pursley J, DiRusso G, Kaul S: Pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept in renal transplant recipients. [Abstract]. Presented at the XXIII International Congress of the Transplantation Society, August 15-19, 2010; Vancouver, Canada. Abstract 1870.2010
22. Vincenti F: Yes there is a benefit to BENEFIT. Am J Transplant 11: 634, 2011
23. Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A, Margreiter R, Hugo C, Grinyo JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF: Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357: 2562-2575, 2007
24. Moore J, Middleton L, Cockwell P, Adu D, Ball S, Little MA, Ready A, Wheatley K, Borrows R: Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: A systematic review and meta-analysis. Transplantation 87: 591605, 2009
25. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia. Report of a WHO/IDFConsultation 2006. International Diabetes Federation. 2011
26. Irish WD, McCollum DA, Tesi RJ, Owen AB, Brennan DC, Bailly JE, Schnitzler MA: Nomogram for predicting the likelihood of delayed graft function in adult cadaveric renal transplant recipients. J Am Soc Nephrol 14: 2967-2974, 2003
27. Parekh J, Bostrom A, Feng S: Diabetes Mellitus: A risk factor for delayed graft function after deceased donor kidney transplantation. Am J Transplant 10: 298-303, 2010